CO2020008308A2 - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
CO2020008308A2
CO2020008308A2 CONC2020/0008308A CO2020008308A CO2020008308A2 CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2 CO 2020008308 A CO2020008308 A CO 2020008308A CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2
Authority
CO
Colombia
Prior art keywords
relaxin
therapeutic use
chain peptides
lipidated
modified
Prior art date
Application number
CONC2020/0008308A
Other languages
English (en)
Inventor
Olivier Duclos
Stéphane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2020008308A2 publication Critical patent/CO2020008308A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como medicamento.
CONC2020/0008308A 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico CO2020008308A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
CO2020008308A2 true CO2020008308A2 (es) 2020-10-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008308A CO2020008308A2 (es) 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (18)

Country Link
US (2) US10961295B2 (es)
EP (1) EP3746467A1 (es)
JP (1) JP7295871B2 (es)
KR (1) KR20200116085A (es)
CN (1) CN111770934A (es)
AR (1) AR114325A1 (es)
AU (1) AU2019214358B2 (es)
BR (1) BR112020014834A2 (es)
CA (1) CA3089657A1 (es)
CO (1) CO2020008308A2 (es)
IL (1) IL276170A (es)
MA (1) MA52994A (es)
MX (1) MX2020008096A (es)
PH (1) PH12020551118A1 (es)
SG (1) SG11202006903WA (es)
TW (1) TWI763972B (es)
UY (1) UY38069A (es)
WO (1) WO2019149782A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149782A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
CN116710462A (zh) 2021-01-20 2023-09-05 维京治疗公司 用于治疗代谢病症和肝病的组合物和方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
BR112014000055A2 (pt) * 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
WO2013017679A1 (en) * 2011-08-04 2013-02-07 Pharis Biotec Gmbh Process for preparing human relaxin-2
US20160152679A1 (en) * 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
KR102302634B1 (ko) * 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
US10266578B2 (en) * 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149782A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
CA3145491A1 (en) * 2019-07-31 2021-02-04 Stacey Lynn Lee Relaxin analogs and methods of using the same

Also Published As

Publication number Publication date
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
UY38069A (es) 2019-08-30
US11725036B2 (en) 2023-08-15
CA3089657A1 (en) 2019-08-08
SG11202006903WA (en) 2020-08-28
US20210292387A1 (en) 2021-09-23
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
RU2020126210A (ru) 2022-02-28
JP2021512099A (ja) 2021-05-13
MA52994A (fr) 2021-05-05
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
PH12020551118A1 (en) 2021-07-05
CN111770934A (zh) 2020-10-13
IL276170A (en) 2020-09-30
TW201940505A (zh) 2019-10-16
JP7295871B2 (ja) 2023-06-21
MX2020008096A (es) 2020-09-24
KR20200116085A (ko) 2020-10-08
BR112020014834A2 (pt) 2020-12-08
US20190233494A1 (en) 2019-08-01
AU2019214358B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2619322T3 (es) Agente inductor de inmunidad
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
UY37705A (es) Nuevos derivados de pirazol bicíclicos
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos